Serum Glycan Markers for Evaluation of Disease Activity and Prediction of Clinical Course in Patients with Ulcerative Colitis

Koji Miyahara1, Kazuhiro Nouso1,2*, Shunsuke Saito1, Sakiko Hiraoka1, Keita Harada1, Sakuma Takahashi1, Yuki Morimoto1, Sayo Kobayashi1, Fusao Ikeda1,2, Yasuhiro Miyake1, Hidenori Shiraha1, Akinobu Takaki1, Hiroyuki Okada1,3, Maho Amano4,5, Kazuko Hirose4, Shin-Ichiro Nishimura4,5, Kazuhide Yamamoto1

1 Department of Gastroenterology & Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Okayama, Japan,
2 Department of Molecular Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Okayama, Japan,
3 Department of Endoscopy, Okayama University Hospital, Okayama, Okayama, Japan,
4 Field of Drug Discovery Research, Faculty of Advanced Life Science & Graduate School of Life Science, Hokkaido University, Sapporo, Hokkaido, Japan,
5 Medicinal Chemistry Pharmaceuticals, Co., Ltd., Sapporo, Hokkaido, Japan

Abstract

Background: The aims of this study were to determine the change of whole-serum N-glycan profile in ulcerative colitis (UC) patients and to investigate its clinical utility.

Methods: We collected serum from 75 UC patients at the time of admission and the same number of age/sex-matched healthy volunteers. Serum glycan profile was measured by comprehensive quantitative high-throughput glycome analysis and was compared with disease activity and prognosis.

Results: Out of 61 glycans detected, 24 were differentially expressed in UC patients. Pathway analysis demonstrated that highly sialylated multi-branched glycans and agalactosyl bi-antennary glycans were elevated in UC patients; in addition, the glycan ratio $m/z$ 2378/1914, which also increased in UC, showed the highest Area under Receiver Operating Characteristic curve (0.923) for the diagnosis of UC. Highly sialylated multi-branched glycans and the glycan ratio $m/z$ 2378/1914 were higher in the patients with total colitis, Clinical Activity Index $>10$, Mayo endoscopic score 3, or a steroid-refractory status. In particular, the glycan ratio $m/z$ 2378/1914 (above median) was an independent prognostic factor for the need for an operation (hazard ratio, 2.67; 95% confidence interval, 1.04–7.84).

Conclusions: Whole-serum glycan profiles revealed that the glycan ratio $m/z$ 2378/1914 and highly sialylated multi-branched glycans increase in UC patients, and are correlated with disease activity. The glycan ratio $m/z$ 2378/1914 was an independent predictive factor of the prognosis of UC.

Introduction

Ulcerative colitis (UC) is a chronic intestinal disorder of unknown etiology with a typically relapsing and remitting course [1]. The evaluation of disease activity is crucial for selecting the therapy and predicting the clinical course, so various laboratory biomarkers [2], clinical indices [3], and endoscopic evaluations [4] have been used simultaneously to determine the activity. An ideal marker is minimally invasive and can be used to monitor the disease activity or predict the clinical course objectively; however, existing clinical indices often use variables subjectively assessed by the patient or a physician, and require endoscopic evaluations that are sometimes invasive and not suitable for routine use.

C-reactive protein (CRP) is one of the most useful markers correlated significantly with the disease activity of UC, and white blood cell count (WBC), platelet, erythrocyte sedimentation rate (ESR) and albumin are also used frequently [2,5,6]. However, CRP was reported to correlate less well with disease activity in UC than in Crohn’s disease (CD) [2,7,8]. In addition, there was concern that some of the existing biomarkers are influenced by...
disease-modifying drugs and corticosteroids [2,9], although the influence on CRP was still unclear [5].

Serum glycans have been reported to be promising diagnostic markers for chronic inflammatory disease, including inflammatory bowel disease (IBD) [10,11]. However, the majority of reported studies investigated glycans attached to a particular protein, such as acute phase proteins or immunoglobulin (Ig) G; therefore, the full picture of the alteration of glycan profile in patients with UC has not been elucidated.

A new technology for glycan-specific enrichment, the “glycoblotting method,” was recently developed [12]. This method enables comprehensive analysis of serum glycans and can achieve high-throughput and quantitative glycomics. The aims of this study were to determine whole glycan expressions in patients with UC using this method and to evaluate the potential use of glycan profiles as new clinical markers for the evaluation of disease activity and for prediction of the clinical course of UC.

Materials and Methods

Patients

Seventy-five patients with UC who were admitted to Okayama University Hospital between January 1997 and December 2007 and the same number of healthy volunteers (HLT) that matched the patients in terms of age and sex were enrolled in this study. We also enrolled 31 CD patients and compared glycan profiles in the patients and that in age sex-matched HLT controls. Seventy-one of UC and 28 of CD patients had already received therapies before admission using aminosalicylate, corticosteroids, mercaptopurine/azathioprine, cyclosporine, leukocytapheresis, and/or elemental diet. The profiles of the patients upon admission and the HLT are shown in Table 1. Median disease duration, defined as the period between the time of onset and the start of the first treatment upon admission during the study period, was 3 and 9 years in UC and CD patients, respectively. Median clinical activity index (CAI) in UC patients was 10, which was composed of seven variables: number of stools, blood in stools, investigator’s global assessment of symptomatic state, abdominal pain or cramps, temperature due to colitis, extraintestinal manifestations, and laboratory findings [13]. Sixteen patients with UC were in symptomatic remission (CAI score <5), who were admitted to have examinations with colonoscopy.

Median Crohn’s disease activity index (CDAI) in CD patients was 138, which was composed of eight variables: number of liquid or very soft stools, abdominal pain score in one week, general wellbeing, sum of physical findings per week, antidiarrheal use, abdominal mass, the values of hematocrit, and percentage deviation from standard weight [14].

Diagnosis and assessment of disease

The diagnosis of UC was based on conventional criteria [15]. Patients without a definite diagnosis of UC or CD (e.g. indeterminate colitis) were excluded. Disease severity of UC was assessed using the extent of disease confirmed by endoscopy, CAI score, and the endoscopic component of the Mayo Scoring System for assessment of UC activity (Mayo endoscopic score): Score 0 = normal, endoscopic remission; Score 1 = mild, erythema, decreased vascular pattern, mild friability; Score 2 = moderate, marked erythema, absent vascular pattern, friability, erosions; and Score 3 = severe, spontaneous bleeding, ulceration [16]. Steroid-refractoriness was defined as little or no improvement after two weeks of systemic steroid therapy (at least 30 mg of prednisolone daily) as previously reported [17].

### Table 1. Characteristics of patients with ulcerative colitis and Crohn’s disease on admission and healthy volunteers.

| Variables | UC (n = 75) | CD (n = 31) | HLT (n = 75) |
|-----------|------------|------------|-------------|
| Age, yr, median (IQR) | 38 (30–54) | 34 (25–39) | 37 (30–50) |
| Male/female | 42/33 | 19/12 | 42/33 |
| Disease duration, yr, median (IQR) | 3 (1–9) | 9 (3–16) | - |
| Disease location, n | | | |
| Total colitis/left-sided colitis | 56/19 | - | - |
| Small bowel/colon/both | - | 10/7/14 | - |
| CAI score, median (IQR) | 10 (5–13) | - | - |
| CDAI score, median (IQR) | - | 138 (101–172) | - |
| Mayo endoscopic score, n, 0/1/2/3 | 0/15/20/40 | - | - |
| Laboratory data, median (IQR) | | | |
| WBC [×10^9/mm³] | 8.5 (6.1–11.3) | 5.6 (4.3–7.9) | - |
| PLT [×10^9/mm³] | 33 (26–45) | 38 (26–44) | - |
| ESR [mm/hr] | 36 (14–67) | 31 (19–55) | - |
| ALB [g/dL] | 3.2 (2.6–3.8) | 3.5 (3.1–4.0) | - |
| CRP [mg/dL] | 0.8 (0.2–4.8) | 0.5 (0.1–2.4) | - |
| Treatment before admission, n (%) | | | |
| Aminosalicylate | 67 (89) | 24 (77) | - |
| Corticosteroids | 52 (69) | 2 (6) | - |
| Mercaptopurine/azathioprine | 13 (17) | 6 (19) | - |
| Cyclosporine | 3 (4) | 0 (0) | - |
| Leukocytapheresis | 20 (27) | 0 (0) | - |
| Elemental diet | 0 (0) | 19 (61) | - |

Abbreviations: ALB, albumin; CAI, clinical activity index; CD, Crohn’s disease; CDAI, Crohn’s disease activity index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLT, healthy volunteers; IQR, interquartile range; PLT, platelet; UC, ulcerative colitis; WBC, white blood cell count.

Glycoblotting

We collected serum from all the patients at the time of admission, and from the HLT. The blood samples were centrifuged for 10 minutes at 15,000 x g, and supernatant were frozen immediately and stored below –30°C until use. Glycoblotting was performed according to a procedure described previously [12]. Briefly, 10 µL serum samples were applied to an automated machine, “Sweetblot” prototype 7 (System Instruments Co.), for pre-treatment and for glycoblotting. After enzymatic cleavage from proteins, glycans were captured on BlotGlyco H beads (Sumitomo Bakelite, Co.), and sialic acids were methyl-esterified. The processed glycans were tagged with benzyloxyamine (BOA) and released from the beads, followed by detection by MALDI-TOF-MS (Ultraflex 3, Bruker, Germany).

Statistical analysis

Student’s t-test was used to compare the continuous data. The clinical course of undergoing operation was compared using the Kaplan-Meier method and evaluated by log-rank test. Cox’s proportional hazards model was used to analyze hazard ratios (HR). The JMP (version 8) software package (SAS Institute, Cary, North Carolina, USA) was used for the analyses and p<0.05 was considered significant. Bonferroni correction was used for multiple comparisons and p<0.05/61 was considered significant for...
evaluation of the difference between the expression in the UC patients and that in the HLT. Pathway analysis was conducted using the Cytoscape program (www.cytoscape.org). To assess the statistical accuracy, validation was implemented by bootstrap methods (10,000 re-sampling) using SAS (version 9.3) software package (SAS Institute, Cary, North Carolina, USA).

Ethics Statement
Written informed consent for taking the serum and using clinical data was obtained from all the patients and the HLT. The study protocol conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki and was approved by the Okayama University Ethics Committee (authorization number #669).

Results
Changes in serum glycan profiles
Glycome analysis by Sweetblot revealed the expression of 61 BOA-labeled glycans with a molecular weight (m/z) ranging from 1362.481 to 4157.522. Five glycans were classified as high-mannose type, six as hybrid type, and 50 as complex type (of these, 25 were bi-antennary, 10 were tri-antennary, and 15 were tetra-antennary). Forty-three glycans were sialylated and 33 contained a fucose moiety. The total glycan level in the serum of UC patients was significantly higher than that of healthy controls regardless of age (Figure 1). In particular, complex type and sialylated glycans were significantly increased in UC, although the expression of high-mannose type, hybrid type, or fucosylated glycans did not differ between UC and HLT.

From 10,000 bootstrap re-sampling, the elevation of complex type and sialylated glycans in UC patients were confirmed. Point estimations of mean values of complex type glycans were 422 pmol/L in UC and 327 pmol/L in HLT (p, 0.0001), and those of sialylated glycans were 355 pmol/L in UC and 270 pmol/L in HLT (p, 0.0001).

Pathway analysis
Pathway analysis was performed to reveal trends in glycan biosynthesis in UC patients (Figure 2). All the samples used in this analysis were obtained from mean values in UC or HLT. Increased biosynthesis of multi-branched (tri- and tetra-antennary) glycans, especially highly sialylated (≥3) glycans, and agalactosyl bi-antennary glycans, which lacked terminal galactose, was clearly observed in UC patients.

Glycans to discriminate between UC and HLT
Among the 61 glycans examined, the expression of 24 glycans differed significantly between UC patients and HLT after Bonferroni correction (Table S1). When we assessed the utility of these glycans for discriminating UC from HLT, glycan m/z 2378 showed the highest Area under Receiver Operating Characteristic curve (AUROC; 0.911) in 14 up-regulated glycans, while glycan m/z 1914 did so in 10 down-regulated glycans (AUROC; 0.844). The ratio of these glycans (m/z 2378/1914) was significantly higher in UC (median, 22.4; interquartile range, 15.9–20.3) than in HLT (median, 10.5; interquartile range, 8.5–12.0; p<0.0001, Student’s t-test), and showed a higher AUROC (0.923) than any single glycan.

Correlation between glycans and clinical manifestations in UC patients
To investigate whether the glycans that increased in UC patients correlated with clinical manifestations of UC, we compared the expression of agalactosyl bi-antennary glycans, highly sialylated (≥3) multi-branched glycans, and the glycan ratio m/z 2378/1914 in association with extent of disease, CAI score, Mayo endoscopic score, and steroid-refractory status (Figure 3). The values of agalactosyl bi-antennary glycans and highly sialylated multi-branched glycans were calculated by summing for four and 13 glycans, respectively. The glycan ratio m/z 2378/1914 (Figure 3A) and the level of highly sialylated multi-branched glycans (Figure 3B) were significantly higher in the patients with...
total colitis, CAI $>$ 10, Mayo endoscopic score 3, or a steroid-refractory status, compared with those with left-sided colitis, CAI $\leq$ 10, Mayo endoscopic score 1–2, or no steroid-refractory status, respectively. On the other hand, the expression of agalactosyl bi-antennary glycans did not differ in association with extent of disease, CAI score, Mayo endoscopic score, and steroid-refractory status.

From 10,000 bootstrap re-sampling, the difference of highly sialylated multi-branched glycans were confirmed. Point estimations of mean values between each clinical manifestations were as follows: left-sided colitis (40.8 pmol/μL) vs. total colitis (58.7 pmol/μL, $p$ < 0.0001), CAI score $\leq$ 10 (46.4 pmol/μL) vs. 10 (63.6 pmol/μL, $p$ < 0.0001), Mayo endoscopic score 1–2 (44.4 pmol/μL) vs. 3 (62.8 pmol/μL, $p$ < 0.0001), and steroid-refractory ‘No’ (40.0 pmol/μL) vs. ‘Yes’ (60.2 pmol/μL, $p$ = 0.001). Those of the glycan ratio $m/z$ 2378/1914 were as follows: left-sided colitis (20.0) vs. total colitis (24.7, $p$ = 0.016), CAI score $\leq$ 10 (20.5) vs. >10 (27.2, $p$ < 0.0001), Mayo endoscopic score 1–2 (19.0) vs. 3 (27.4, $p$ < 0.0001), and steroid-refractory ‘No’ (19.6) vs. ‘Yes’ (27.3, $p$ < 0.0001).

The utility of glycan markers for predicting disease prognosis

To evaluate the utility of glycan markers for predicting disease prognosis, we compared the rate of proctocolectomy between the patients with high and low values of glycan ratio $m/z$ 2378/1914 and highly sialylated multi-branched glycans, as well as existing biomarkers: WBC, platelet, ESR, albumin, and CRP. The patients with high values of glycan ratio $m/z$ 2378/1914 showed a shorter time to operation than those with low values (cut-off, median; $p$ = 0.0006: Figure 4). The HR (above the median) for requiring an operation was higher for glycan ratio $m/z$ 2378/1914 (HR, 4.33; 95% confidence interval (CI), 1.85–11.8), as well as CAI, $>$ 10 (HR, 4.13; 95% CI, 1.86–10.0) and Mayo endoscopic score, 3 (HR, 5.10; 95% CI, 2.19–13.9) than for the highly sialylated multi-branched glycans (HR, 3.04; 95% CI, 1.37–7.39), CRP (HR, 2.47; 95%CI, 1.13–5.79), or other existing biomarkers in univariate analysis (Table 2). In addition, the glycan ratio $m/z$ 2378/1914 was an independent prognostic factor for requiring an operation in multivariate analysis, when only variables that demonstrated a $p$-value $<$0.1 in univariate analysis were entered into the multiple logistic regression model.

Glycan profiles in CD

We detected 18 glycans (15 up-regulated and 3 down-regulated) that were differentially expressed between CD patients and HLT (Table S2). The expression profile in CD was similar to that in UC, and eleven out of the 18 glycans were the same. In addition, glycan $m/z$ 2378/1914 (AUROC; 0.948) and $m/z$ 1914 (AUROC; 0.879) showed the highest AUROC in 15 up-regulated and in 3 down-regulated glycans, respectively.

Discussion

This study first analyzed whole-serum N-glycan profiles in UC patients using Sweetblot, a high-throughput and automated glycomics system that can measure glycans comprehensively and quantitatively. The total amount of N-glycans was elevated in UC patients, and pathway analysis demonstrated that the increased biosynthesis was remarkable for highly sialylated multi-branched glycans and agalactosyl bi-antennary glycans. In addition, we also found that a particular glycan ratio ($m/z$ 2378/1914) was significantly higher in UC than in HLT. Serum expression of highly sialylated multi-branched glycans and the glycan ratio $m/z$
2378/1914 were well correlated with clinical manifestations of UC, such as the extent of disease, CAI score, Mayo endoscopic score, and steroid-refractory status, and the results were validated by using bootstrap method. Furthermore, the expression of the glycan ratio $m/z$ 2378/1914 was an independent prognostic factor for requiring an operation. The expression of glycans in UC was similar to that in CD.

Glycans with multiple branches, sialylation, and a consequently induced sialyl Lewis X (SLex) epitope, which involves the structure of outer branch fucosylation and sialylation [18] and is related to leukocyte-endothelial adhesion [19], were reported to increase in various chronic inflammatory diseases, including rheumatoid arthritis [20], Crohn’s disease [21], and cancers [21–23]. These alterations of glycan were shown on acute-phase proteins such as haptoglobin [20–22] and alpha 1-acid glycoprotein [24–26], and were considered to be common features of long-term inflammation [10]. However, SLex epitope was observed in only two glycans ($m/z$ 3341 and 4011) among the 24 glycans in our study examining UC patients. This might have been because the SLex epitope was down-regulated by prior therapies including corticosteroids [27]. On the other hand, the glycan $m/z$ 2378, which is a fully sialylated bi-antennary glycan, showed a higher AUROC for the diagnosis of UC than all other glycans with multiple branches and/or SLex epitope. Interestingly, this glycan retained its correlation with CAI score even in patients treated with a high dose of corticosteroids ($50 \text{ mg of prednisolone daily}$), whereas many other glycans or existing biomarkers did not (data not shown). This observation indicates that glycan $m/z$ 2378 would be suitable as a biomarker of UC patients with prior therapies, and it is the best for predicting prognosis when divided by the value of glycan $m/z$ 1914. In addition, our preliminary study with autoimmune hepatitis and autoimmune pancreatitis showed no elevation of the ratio ($m/z$ 2378/1914) so that the elevation might be specific phenomenon in UC and CD patients (data not shown).

Figure 3. Differentially expressed serum glycans with characteristics of ulcerative colitis. Box-plot of (A) the glycan ratio $m/z$ 2378/1914 and (B) highly sialylated multi-branched glycans, which were significantly higher in the patients with total colitis, Clinical Activity Index $>10$, Mayo endoscopic score 3, or a steroid-refractory status, compared with left-sided colitis, Clinical Activity Index $\leq 10$, Mayo endoscopic score 1–2, or no steroid-refractory status, respectively.

doi:10.1371/journal.pone.0074861.g003

Figure 4. Clinical course of requiring surgery in patients with high and low values of the glycan ratio $m/z$ 2378/1914. Kaplan-Meier plot of the patients with high (solid line) and low (dotted line) values of the glycan ratio $m/z$ 2378/1914 (cut-off: median). Time to operation was significantly shorter in patients with high values than in those with low values of the glycan ratio $m/z$ 2378/1914 ($p = 0.0006$; log-rank test).

doi:10.1371/journal.pone.0074861.g004
The biological implications of the glycan group so that the specificity with this setting is 92.9% and the m/z glycans seem to correlate with inflammation. The glycan change of glycan profiles over the clinical course. Secondly, we measured at only one point, so we did not evaluate patients, there are several limitations to this study. Firstly, it involved retrospective analysis with a small sample size, and the majority of patients (71 out of 75) had already received therapies before admission, which might have influenced the serum levels of glycans upon admission. In addition, we could not clarify whether alterations of serum glycan were caused by alteration of carrier protein profile or by modification of attached glycans by this method. Further examination to find out ligands of each glycan and the biological effects of glycan alterations are necessary.

Despite these limitations, we first demonstrated whole-serum glycans in UC patients and clearly demonstrated that the glycan ratio m/z 2378/1914 was the best predictive factor for the prognosis of UC among the markers measured in this study. However, further prospective and longitudinal studies are needed to confirm these results.

Supporting Information

Table S1 Differentially expressed serum glycans in patients with ulcerative colitis.

Table S2 Differentially expressed serum glycans in patients with Crohn’s disease.

Author Contributions

Conceived and designed the experiments: KN S-IN KY. Performed the experiments: MA K. Hirose. Analyzed the data: KM KN AT HO. Contributed reagents/materials/analysis tools: FI Y. Miyake HS. Wrote the paper: KM KN. Acquired the clinical data: SS SH K. Harada ST Y. Morimoto SK.
References

1. Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641–1657.

2. Vermeire S, Van Asche G, Rutgeerts P (2006) Laboratory markers in IBD: useful, magic, or unnecessary tools? Gut 55: 420–431.

3. Mowat C, Cole A, Windsor A, Ahmad T, Arnett T, et al. (2011) Guidelines for the management of inflammatory bowel disease in adults. Gut 60: 371–607.

4. Simpson P, Papadakis KA (2008) Endoscopic evaluation of patients with inflammatory bowel disease. Inflamm Bowel Dis 14: 1287–1297.

5. Henriksen M, Jahnens J, Lygren I, Stroy N, Sauer J, et al. (2008) C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 57: 1518–1523.

6. Vilela EG, Torres HO, Martins FP, Ferrari Mde L, Andrade MM, et al. (2012) Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis. World J Gastroenterol 18: 872–881.

7. Peppi MB, Druguet M, Klass HJ, Dush AC, Mirjah DD, et al. (1977) Immunological studies in inflammatory bowel disease. In: Porter R, Knight J, editors. Immunology of the gut, Ciba Foundation Symposium. Amsterdam: Elsevier, Excerpta Medica. North Holland: 283–297.

8. Sawyer-Matt H, Hodgson JH, Chadwick VS, Pepys MB (1986) Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 27: 809–813.

9. Breda L, Nozzi M, De Sanctis S, Chiarelli F (2010) Laboratory tests in the diagnosis and follow-up of pediatric rheumatic diseases: an update. Semin Arthritis Rheum 40: 53–72.

10. Arnold JN, Saldeva R, Hamid UM, Rudd PM (2008) Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 8: 3284–3293.

11. Shinzaki S, Iijima H, Fujii H, Kuroki E, Tatsunaka N, et al. (2012) Altered N-glycan Changes in Ulcerative Colitis

12. van Dijk W, Havenaar EC, Brinkman-van der Linden EC (1995) Alpha 1-acid glycoprotein (orosomucoid): Pathophysiological changes in glycosylation in relation to its function. Glycocon J 12: 227–233.

13. Fassbender K, Zimmerli W, Kissing R, Sobieska M, Aeschlimann A, et al. (1991) Glycosylation of alpha 1-acid glycoprotein in relation to duration of disease in acute and chronic infection and inflammation. Clin Acta 203: 315–327.

14. Mackiewicz A, Mackiewicz K (1995) Glycoforms of serum alpha 1-acid glycoprotein as markers of inflammation and cancer. Glycocon J 12: 241–247.

15. Ishida H, Koyama I, Sawada T, Murakami T, Usunuki K, et al. (2000) Clinical utility of high-throughput glycan analysis in patients with pancreatic cancer. J Gastroenterol [In press].

16. Oxford JS, Sumar N, Alavi A, Isemberg DA, Young A, et al. (1992) Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. J Clin Invest 89: 1021–1031.

17. Nakajima S, Iijima H, Shinzaki S, Egawa S, Inoue T, et al. (2011) Functional analysis of agalactosyl IgG in inflammatory bowel disease patients. Inflamm Bowel Dis 17: 927–938.

18. Bekescs O, Keski O, Chandler KB, Wu J, Madej HL, et al. (2012) N-glycans in liver-secreted and immunoglobulin-derived protein fractions. J Proteomics 75: 2216–2224.

19. Shinzaki S, Iijima H, Fuji H, Kuros K, Tatsunaka N, et al. (2012) Altered oligosaccharide structures reduce colitis induction in mice defective in 6-1,4-galactosyltransferase. Gastroenterology 142: 1172–1182.

20. Azuma Y, Murata M, Matsumoto K (2000) Alteration of sugar chains on alpha(1)-acid glycoprotein secreted following cytokine stimulation of Hu-H-7 cells in vitro. Clin Chim Acta 294: 93–103.